FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Impact of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy on pCR and Tumor Downstaging in Resectable Gastric Cancer: A Meta-Analysis. PMID 42512335 · Cancers (Basel) · 2026-Jul-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Psychometric Evaluation of the PRO-CTCAE Average Composite Score: Reliability, Responsiveness, Known-Groups Validity, and Sensitivity to Group Differences. PMID 42512331 · Cancers (Basel) · 2026-Jul-15 The record is a psychometric validation study of the PRO-CTCAE Average Composite Score. While it uses data from a Phase III randomized trial (COMET-2), the report's primary purpose is to evaluate the measurement properties of a patient-reported outcome instrument, not to present the trial's efficacy results (e.g., OS, PFS, HR). Therefore, it does not meet the criteria for an original formal-result report of a drug-containing intervention with a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Recurrence Score® gene group components and outcomes in the RxPONDER trial (SWOG S1007). PMID 42458791 · J Natl Cancer Inst · 2026-Jul-15 This is an original report of a randomized trial (RxPONDER) with a drug intervention (endocrine therapy ± chemotherapy) and a time-to-event endpoint (IDFS). However, it is not a primary or key secondary result report for the overall trial efficacy. The analysis is a pre-specified subgroup/biomarker analysis focusing on gene expression components and disparities by ethnicity, not the primary trial outcome. The phase is not explicitly stated in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Asciminib as first-line therapy in chronic myeloid leukemia: a systematic review. PMID 42458108 · Blood Res · 2026-Jul-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Advanced and Salvage Techniques for Difficult Biliary Cannulation in ERCP: A Randomized Trial of Outcomes and Efficacy. PMID 42456983 · Gastrointest Endosc · 2026-Jul-15 The record is not an oncology Kaplan-Meier digitization cohort eligible study. It is a randomized trial in gastroenterology evaluating procedural techniques, not a drug intervention for human malignant neoplasm with a primary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Dose-escalated versus Standard Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: 9-year Results of a Randomized Phase 2 Trial. PMID 42456783 · Int J Radiat Oncol Biol Phys · 2026-Jul-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Clinical Study on the Prevention of High-Risk Pulmonary Nodule Progression With Yifei Sanjie Pill: Protocol for a Multicenter Randomized Controlled Trial. PMID 42456132 · JMIR Res Protoc · 2026-Jul-15 The record is a protocol for a randomized, placebo-controlled trial. While it meets criteria for oncology, human, randomized, drug intervention, and a time-to-event primary endpoint, it is explicitly a protocol without reported results. Furthermore, the trial phase is not specified as Phase III/IIIb or Phase II/III, which is a required eligibility criterion. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Combining VEGFR tyrosine kinase inhibitors and PD-1/PD-L1 inhibitors versus VEGFR tyrosine kinase inhibitors monotherapy in renal cell carcinoma: a target trial emulation. PMID 42428070 · medRxiv · 2026-Jul-15 The record is an observational cohort study using target trial emulation with propensity score matching, not a randomized Phase III trial. Although it involves oncology, human patients, drug interventions, and time-to-event endpoints (OS), the lack of randomization and confirmed Phase III/IIIb or Phase II/III status makes it ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-term benefit from adjuvant tamoxifen therapy for ER+ HER2- breast cancer by PR positivity. PMID 41787605 · Int J Cancer · 2026-Jul-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Comparing the effectiveness of prostate cancer screening protocols: European Association of Urology- and European Randomized Study of Screening for Prostate Cancer-based strategies. PMID 41741956 · Int J Cancer · 2026-Jul-15 Study is a microsimulation modeling analysis comparing prostate cancer screening strategies; it is not a Phase III/IIIb or Phase II/III randomized trial of a drug intervention with a primary time-to-event efficacy endpoint (e.g., OS, PFS). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Consolidation Chemotherapy After Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: 7-Year Follow-Up Results of a Randomized Multicenter Trial (KCSG CO 14-03). PMID 41548612 · Int J Radiat Oncol Biol Phys · 2026-Jul-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up. PMID 42447419 · J Clin Oncol · 2026-Jul-14 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant nedaplatin and paclitaxel regimen with concurrent radiotherapy for esophageal squamous cell carcinoma: a single-arm phase II clinical trial. PMID 42446091 · Future Oncol · 2026-Jul-14 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms. PMID 42443407 · Leukemia · 2026-Jul-13 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Avatrombopag Versus Placebo for Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancers: The Phase II ACT-GI Trial. PMID 42441933 · J Clin Oncol · 2026-Jul-13 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Prognosis of Recurrent Venous Thromboembolism During Extended Apixaban Therapy for Cancer-Associated Thrombosis: Insights From the API-CAT Randomized Trial. PMID 42439484 · Circulation · 2026-Jul-13 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| An intervention for fear of progression in childhood cancer patients and their parents: feasibility and preliminary efficacy in a pilot randomised controlled trial. PMID 42437909 · BMC Pediatr · 2026-Jul-13 The record is a pilot RCT of a psychotherapeutic intervention in pediatric oncology. It is randomized and original, but it is excluded because it does not meet the drug intervention and time-to-event endpoint criteria required for inclusion. The phase is not explicitly stated but is likely early-phase (pilot), not definitively Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism in Patients With Cancer: A Randomized Clinical Trial. PMID 42437322 · JAMA · 2026-Jul-12 The study is a randomized clinical trial in human oncology patients, but it is excluded because it does not meet all required criteria: it lacks a drug-containing intervention and a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The primary outcome is a composite clinical endpoint (symptomatic VTE or PE-related death) reported as risk differences and proportions, not a time-to-event analysis. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Dosimetric analysis of post-radiotherapy sexual dysfunction in patients receiving definitive stereotactic body radiotherapy (SBRT) for prostate cancer: a secondary analysis of MIRAGE. PMID 42435817 · Radiother Oncol · 2026-Jul-11 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of Gross's emotion regulation training on death anxiety in leukemia patients undergoing chemotherapy: a randomized controlled trial. PMID 42432782 · BMC Psychol · 2026-Jul-11 The study is a randomized controlled trial in oncology (leukemia patients) with a drug-containing intervention (chemotherapy), but it is not a Phase III/IIIb or Phase II/III trial, and its primary endpoint is death anxiety (a quality-of-life outcome), not a time-to-event efficacy endpoint such as OS, PFS, DFS, etc. Therefore, it does not meet all criteria for inclusion in the Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Home-based high-intensity exercise training during neoadjuvant chemotherapy is associated with favorable chemotherapy outcomes and tumor microenvironment remodeling in breast cancer. PMID 42432678 · Cell Commun Signal · 2026-Jul-10 The record describes a randomized trial of exercise (HIIT) during neoadjuvant chemotherapy in breast cancer. While it is an original result report with a drug intervention (neoadjuvant chemotherapy), it fails key eligibility criteria: the trial phase is not stated as Phase III or Phase II/III (it is likely a Phase II or exploratory study), and the primary endpoint is pathological response (Miller-Payne grade), not a time-to-event efficacy endpoint such as OS, PFS, DFS, or any reported Kaplan-Meier/HR analysis. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Adjuvant penpulimab in very-high risk clear cell renal cell carcinoma: a prospective, non-randomized, controlled phase II trial with integrated plasma multi-omics analyses. PMID 42431710 · J Immunother Cancer · 2026-Jul-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant Chemotherapy with Trastuzumab with or without Concurrent Radiotherapy in HER2-Positive Locally Advanced Inoperable Breast Cancer- A Phase 2 Randomized Controlled Trial (NEOTRAC STUDY). PMID 42431330 · Int J Radiat Oncol Biol Phys · 2026-Jul-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Acute toxicity and quality of life with stereotactic body radiotherapy versus conventional fractionated intensity-modulated radiotherapy to the prostate and pelvis in high-risk prostate cancer (SRAM): A randomized phase II trial. PMID 42431329 · Int J Radiat Oncol Biol Phys · 2026-Jul-10 The trial is a randomized Phase II oncology study in humans, but it fails the eligibility criteria because it is not Phase III/IIIb or a definitive Phase II/III, its primary endpoint is acute toxicity (not a time-to-event efficacy endpoint), and it does not test a drug-containing intervention as the experimental arm. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Evaluating a Tailored Web-Based eHealth Intervention for Symptom Management in Couples Managing Prostate Cancer During the COVID-19 Pandemic: Randomized Clinical Trial. PMID 42430132 · J Med Internet Res · 2026-Jul-10 The study is a randomized trial in prostate cancer patients but evaluates an eHealth intervention (PERC) for symptom management and quality of life. It does not involve a drug-containing intervention and does not have a time-to-event efficacy endpoint (e.g., OS, PFS). Therefore, it is ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials. PMID 42212672 · J Clin Oncol · 2026-Jul-10 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Addition of Intravesical Recombinant Bacillus Calmette-Guérin to Perioperative Chemoimmunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/19. PMID 42212670 · J Clin Oncol · 2026-Jul-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study. PMID 42190158 · J Clin Oncol · 2026-Jul-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Impact of lead-in ADT on grade ≥3 neutropenia in patients with metastatic hormone-sensitive prostate cancer treated with triplet therapy. PMID 42127891 · Med · 2026-Jul-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Perioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of NEOSUMMIT-01 Trial. PMID 42085639 · J Clin Oncol · 2026-Jul-10 The record describes a randomized, drug-interventional oncology trial with primary time-to-event efficacy endpoints (EFS, OS) reported as original results. The phase is not explicitly stated in the abstract, but the trial is large (n=108), randomized, and reports definitive efficacy results typical of a Phase III/II-III trial, meeting the 'phase3_or_definitive' criterion. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors. PMID 42066233 · J Clin Oncol · 2026-Jul-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors. PMID 42426863 · J Hematol Oncol · 2026-Jul-09 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Anti-HER2 Therapies in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. PMID 42426557 · Oncologist · 2026-Jul-09 The record is a systematic review and meta-analysis of multiple clinical trials, not an original report of a single randomized Phase III or Phase II/III trial. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Re: Murthy V, Maitre P, Pal M, et al. Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-invasive Bladder Cancer. J Clin Oncol. In press. http://dx.doi.org/10.1200/JCO-25-02093. PMID 42425857 · Eur Urol · 2026-Jul-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Effects of a fasting-mimicking diet on long-term prognosis in patients with colorectal cancer undergoing radical resection: protocol for a multicentre, prospective, randomised controlled trial. PMID 42425570 · BMJ Open · 2026-Jul-09 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Aspirin for cancer prevention in individuals with Lynch syndrome: first results from the CaPP3 multicentre, randomised, double-blind, non-inferiority trial. PMID 42425127 · Lancet Gastroenterol Hepatol · 2026-Jul-09 The record meets all criteria: it is an original, human, randomized, Phase III-level trial of a drug intervention (aspirin) with a primary time-to-event efficacy endpoint (time to first Lynch syndrome cancer) reported with HRs and IRRs. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| RecoverEsupport-A Digital Health Intervention for Recovery After Breast Cancer Surgery: Feasibility and Acceptability Outcomes from a Pilot Randomized Controlled Trial. PMID 42424596 · JMIR Form Res · 2026-Jul-09 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Consolidative Thoracic Radiotherapy With Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: The Phase 2 TREASURE Randomized Clinical Trial (AIO-TRK-0320). PMID 42424047 · JAMA Oncol · 2026-Jul-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Setmelanotide for the Treatment of Acquired Hypothalamic Obesity. PMID 42418774 · N Engl J Med · 2026-Jul-09 This is a Phase III randomized trial of a drug (setmelanotide) for acquired hypothalamic obesity, not a malignant neoplasm. While it meets criteria for being human, randomized, Phase III, drug-intervention, and original-result, it is not oncology. Furthermore, the primary endpoint is mean percent change in BMI, which is not a time-to-event efficacy endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Perioperative Nivolumab and Ipilimumab with Chemotherapy and Chemoradiation for Resectable Gastric and Gastroesophageal Junction Adenocarcinoma: A Phase 1/2 Non-Randomized Clinical Trial. PMID 42512265 · Cancers (Basel) · 2026-Jul-08 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Robotic right hemicolectomy with intracorporeal anastomosis versus laparoscopic right hemicolectomy with extracorporeal anastomosis (PRORHEM): protocol for a randomized controlled trial. PMID 42420958 · BMC Surg · 2026-Jul-08 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Patterns of presentation and outcomes in stage IV Hodgkin lymphoma: A report from the Children's Oncology Group (COG) AHOD1331 trial. PMID 42419755 · Br J Haematol · 2026-Jul-08 The record is a randomized, drug-interventional trial with a primary time-to-event endpoint (PFS). However, it is a subgroup analysis of the main trial results, and the trial phase is not explicitly stated in the metadata. While it is likely a Phase III trial based on the cooperative group and randomization, the explicit phase cannot be established from the provided text. Therefore, is_eligible is set to null. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Venetoclax in combination with cytarabine with or without idarubicin or azacitidine in children, adolescents, and young adults with relapsed or refractory acute myeloid leukaemia (VENAML): a multicentre, phase 1 expansion study. PMID 42419338 · Lancet Haematol · 2026-Jul-08 The record describes a phase 1 expansion study, not a randomized Phase II/III or Phase III/IIIb trial, and does not report a primary or key secondary time-to-event efficacy endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy, Safety, and Mechanism of the Qi-Lian-Xiao-Pi Prescription (WW-1) for Chronic Atrophic Gastritis After Helicobacter Pylori Eradication: Protocol for a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. PMID 42418263 · JMIR Res Protoc · 2026-Jul-08 The record is a protocol for an ongoing trial of a traditional Chinese medicine for a precancerous lesion (chronic atrophic gastritis), not a human malignant neoplasm. It lacks a primary/key secondary time-to-event efficacy endpoint and does not report formal results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Corticosteroid-sparing effects of risankizumab versus ustekinumab in patients with moderately to severely active Crohn's disease: post hoc results from the phase 3b SEQUENCE trial. PMID 42479626 · J Crohns Colitis · 2026-Jul-07 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Everolimus and de novo malignancies after liver transplantation: a Nationwide Emulated Trial Using Real-World Data. PMID 42413767 · JHEP Rep · 2026-Jul-07 The study is a non-randomized, observational analysis using an 'emulated target trial' framework. While it is oncological, involves humans, has a drug intervention, and reports time-to-event efficacy results, it fails the core requirement of being a randomized controlled trial and does not have an explicitly stated Phase III/IIIb or Phase II/III classification. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Transportability of tislelizumab trial outcomes from RATIONALE-315, RATIONALE-303, and RATIONALE-312 to the European population in early-stage non-small cell lung cancer (NSCLC), advanced NSCLC and extensive-stage small cell lung cancer (ES-SCLC). PMID 42412689 · Future Oncol · 2026-Jul-07 The record describes a modeling and transportability analysis (a 'Targeted literature review' and 'Outcome regression models') using data from other trials (RATIONALE-315, RATIONALE-303, RATIONALE-312). It is not a primary, original result report of a Phase III randomized trial with a drug intervention and a time-to-event endpoint. The publication is a secondary analysis, likely a health-economic or modeling study. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cost-Effectiveness of Fecal Immunochemical Testing Alone vs Co-Testing With Helicobacter pylori Stool Antigen. PMID 42223961 · JAMA · 2026-Jul-07 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effect of endoscopic screening for non-cardia gastric cancer: a 12-year report of a population-based randomized trial. PMID 42410417 · BMC Med · 2026-Jul-06 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Laparoscopic versus open pancreaticoduodenectomy for non-pancreatic periampullary adenocarcinomas: study protocol for a multicentre randomised controlled trial in China. PMID 42409398 · BMJ Open · 2026-Jul-06 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |